- Value
- Analytics
- Backtesting
- Options
- Resources
Go Prime
Option Strategy
Gift Nifty
Gold Price Today
Silver Price Today
Download Now
For Android & IOSMy Profile
My Dashboard
My Watchlist
My Alerts
My Portfolio
Share a Trial
Change Password
Logout
Price Table
* Prices are based on daily market changes.
Date | Open | High | Low | Close | Volume | Delivery % | 20-Day sma | 50-Day sma | 200-Day sma |
---|---|---|---|---|---|---|---|---|---|
17 Mar, 2025 | 670.00 | 678.85 | 663.90 | 675.15 | 28,26,617 | 86.26 | 683.60 | 747.15 | 808.85 |
13 Mar, 2025 | 681.00 | 683.40 | 663.20 | 666.20 | 3,94,603 | 68.81 | 684.95 | 750.75 | 808.90 |
12 Mar, 2025 | 689.90 | 697.00 | 666.45 | 676.60 | 5,27,417 | 62.86 | 687.15 | 754.90 | 808.90 |
11 Mar, 2025 | 682.10 | 685.95 | 674.15 | 681.80 | 3,95,107 | 28.30 | 689.40 | 758.95 | 808.90 |
10 Mar, 2025 | 677.00 | 684.10 | 669.55 | 677.65 | 3,97,534 | 60.79 | 692.15 | 762.50 | 808.95 |
07 Mar, 2025 | 693.25 | 693.80 | 677.85 | 679.65 | 2,27,156 | 44.66 | 695.50 | 766.15 | 809.05 |
06 Mar, 2025 | 680.00 | 690.40 | 677.60 | 688.55 | 3,75,799 | 58.18 | 698.85 | 769.55 | 809.15 |
View More
Day High Low Range
Time | Lowest | Highest | Volume |
---|---|---|---|
09.30 AM | 663.90 | 671.70 | 26004.00 |
09.45 AM | 663.90 | 673.30 | 1054340.00 |
10 AM | 663.90 | 678.85 | 1451787.00 |
11 AM | 663.90 | 678.85 | 1821564.00 |
12 PM | 663.90 | 678.85 | 1988202.00 |
1 PM | 663.90 | 678.85 | 2035679.00 |
2 PM | 663.90 | 678.85 | 2187538.00 |
3 PM | 663.90 | 678.85 | 2709101.00 |
Past Performance & Moving Averages
Day’s | Low high range | SMA | Stock performance | Nifty performance |
---|---|---|---|---|
10 DAY | 636.30 - 697.00 | 672.86 | -1.72% | -0.3% |
20 DAY | 636.30 - 726.00 | 683.62 | -3.01% | -0.52% |
50 DAY | 636.30 - 895.75 | 747.13 | -12.4% | -1.71% |
100 DAY | 636.30 - 960.60 | 812.07 | -21.81% | -8.88% |
200 DAY | 607.65 - 960.60 | 808.85 | -20.38% | -10.41% |
YTD | 636.30 - 895.75 | 754.08 | -22.03% | -4.95% |
52 Week | 607.65 - 960.60 | 786.07 | -6.57% | -7.23% |
PIVOT POINTS
NAME | S4 | S3 | S2 | S1 | PIVOT POINTS | R1 | R2 | R3 | R4 |
---|---|---|---|---|---|---|---|---|---|
CLASSIC | - | 638.27 | 650.73 | 658.47 | 670.93 | 678.67 | 691.13 | 698.87 | - |
WOODIE‘S | - | - | 649.55 | 656.10 | 669.75 | 676.30 | 689.95 | - | - |
FIBONACCI | - | 650.73 | 658.45 | 663.22 | 670.93 | 678.65 | 683.42 | 691.13 | - |
CAMARILLA | 655.09 | 660.65 | 662.50 | 664.35 | - | 668.05 | 669.90 | 671.75 | 677.31 |
CPR Levels
LTP: 675.15
PDH: 683.40
PDL: 663.20
S4
642.73
S3
651.47
S2
657.68
S1
666.42
| CPR |
BC: 671.38
P: 672.63
TC: 673.89
R1
681.37
R2
687.58
R3
696.32
R4
702.53
- SYNGENE is currently trading Above CPR levels which signifies Bullishness.
- Today's CPR is comparatively Average.
- Day's opening range is 663.9 ~ 671.7.
- Price is currently trading Inside the day's opening range.
Trend Analysis
Short term trend: Down
Medium term trend: Down
Long term trend: Not Clear
Key Data
Market cap | Book value | stock p/e | Dividend yield | roce | roe | sales growth (3Y) | face value (3Y) |
---|---|---|---|---|---|---|---|
27168.11 CR. | 106.00 | 58.60 | 0.16% | 14.70% | 13.20% | 17.00% | 10.00 |
Profile
SYNGENE
It was incorporated as Syngene International Private Limited as on November 18, 1993, at Bengaluru, Karnataka as a private limited company under the Companies Act, 1956. According to a special resolution of the shareholders dated March 26, 2007, the Company was being converted into a public limited company, and the company name was changed to Syngene International Limited. Also, a fresh certificate of incorporation consequent upon conversion to the public limited company was issued as on April 19, 2007. It was also promoted by Kiran Mazumdar Shaw, who is a promoter of Biocon. On March 30, 2002, 99.9% of the Equity Shares of the Company were being transferred to Biocon, and as a result, it became the subsidiary of Biocon. It has also since been the Promoter of the Company. Also, the details of changes in the registered office of the Company are given below: From 20th KM, Hosur Road, Electronics City P.O, Bengaluru 560 100, Karnataka, India to Biocon Special Economic Zone, Biocon Park, Plot No. 2 and 3, Bommasandra Industrial Area IV Phase, Jigani Link Road, Bommasandra, Bengaluru 560 099, Karnataka, India.Some of the Milestones:
- 1994: It initiated operations as a CRO with services in chemistry and biology.
- 1998: It granted 100% Export Oriented Unit (EOU) status by the Government of India.
- 1999: Its first operational expansion in R&D by way of expansion of lab space to over 23,000 sq. Ft.
- 2000: Also, CIL was incorporated as a 100% subsidiary of Biocon to provide clinical research services to domestic and multinational companies.
- 2001: It forayed into chemical development with a dedicated manufacturing facility.
- 2003: It moved to Biocon Park, a 90-acre biopharmaceutical SEZ with the operations spread over 65,000 sq. Ft.
- 2007:
- Both Bristol-Myers Squibb and the Company signed the first long term contract to set up the first dedicated R&D center.
- The expansion of research facilities located at Biocon SEZ to 148,000 sq. Ft.
- It crossed an annual turnover of over `1,000 million in Financial Year 2007.
- 2009:
- Both Dupont Crop Protection and the Company extended a partnership for R&D services.
- The expansion of manufacturing services with a new plant which is cGMP compliant.
- It initiated operations in safety assessment and large molecules development services.
- 2010:
- Also, the acceptance of the clinical and bio-analytical facilities of CIL by the Department of Health & Human Services, FDA.
- It initiated operations in formulation development.
- 2011: Both Endo Pharmaceuticals and the Company collaborated to develop novel biological therapeutic molecules against cancer.
- 2012:
- Both Abbott and the Company collaborated to establish Abbott's nutrition research and development center in India and the second R&D center.
- It received the certification of the clinical facilities by ANVISA.
- It acquired a 100% stake in Clinigene International Limited from Biocon.
- 2013:
- It crossed an annual turnover of over INR 5,000 million in Financial Year 2013.
- Also, the Baxter International Inc. collaborated with the Company to establish the ‘Baxter Global Research Center,’ the third dedicated R&D center.
- The acceptance of the control testing laboratory by the Department of Health & Human Services, FDA.
- 2014:
- Both Bristol-Myers Squibb and the Company extend collaboration for its dedicated R&D center till 2020.
- The acceptance of the API manufacturing facility by the Department of Health & Human Services, FDA.
- It also established a 75,000 sq.ft center to provide stability and analytical services.
- 2015: Also, the CIL was amalgamated with the Company.
Some of the Achievements:
- 2009:
- It received Bangalore Bio, Bio Excellence Award, in Biotech Services Sector.
- It won the Best BioServices Company of the year from Biospectrum.
- 2012:
- It received ISO 9001:2008 for contract research in drug discovery and contract manufacturing of biopharmaceuticals.
- It received AAALAC accreditation for conforming to the “Guide for the Care and Use of Laboratory Animals and the Committee for Control & Supervision of the Experiments on Animals guidelines.”
- 2013:
- It received Bioservices - ABLE Tenth Anniversary Award for the outstanding contribution to Bioservices.
- It received Diamond Sponsor recognition by the Association of Scientists of Indian Origin of the Society of Toxicology.
- 2014:
- It received ISO 14001:2004 for contract research in drug discovery and contract manufacturing of biopharmaceuticals.
- It received BS OHSAS 18001:2007 for contract research in drug discovery and contract manufacturing of biopharmaceuticals.
- It received a Silver EDGE Award.
- It received the EHS best practices award by CII.
- It received SAP Ace Award for special recognition for complex SAP implementation.
- 2015:
- Also, the accreditation by the College of American Pathologists concerning their laboratory accreditation program.
- It received Bangalore India Bio - Bio Excellence Award for an outstanding contribution to the Biotech services sector.
- It received ISO 15189:2007 in the field of medical testing.
- 2017:
- Both Herbalife Nutrition Partners with Syngene to Establish Nutrition Research and Development Lab in India.
- The "Syngene International Announces Broadening of Research Collaboration with Amgen Inc." and expands the Dedicated R&D Center.
- Both "Bristol-Myers Squibb and Syngene International Expand for an Ongoing Research Collaboration."
TRADER’S TOOLKIT
